Medicine
Barhemsys 5 mg/2 mL injection
Barhemsys 5 mg/2 mL injection is a prescription medicine containing Amisulpride for intravenous use, marketed by Acacia Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store vials at 20°C to 25°C (68°F to 77°F). Protect from light.
Key facts
- Active ingredient (INN)
- Amisulpride
- Brand
- Barhemsys
- Strength
- 5 mg/2 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 10 cartons of 2 mL
- Marketing authorisation holder
- Acacia Pharma
- Manufacturer
- Acacia Pharma
- Origin register
- US FDA, United States
- Storage
- Store vials at 20°C to 25°C (68°F to 77°F). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N05AL05 Amisulpride
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 27 February 2020
- Identifiers
- RxCUI 2284232, 2284237, 2467148 +1DailyMed set ID ab23bc6e-b6a8-165f-e053-2a95a90ab144NDC 71390-125Application NDA209510
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 carton in 1 package / 1 vial, single-dose in 1 carton / 2 mL in 1 vial, single-dose | 71390-125-20 | Acacia Pharma | 27 February 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 26 February 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Amisulpride
Clinical summary
Amisulpride is a dopamine-2 receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. It is available as injection for intravenous use. MedsAcross supplies Amisulpride for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AmisulprideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Barhemsys prescribing information (Acacia Pharma) · U.S. National Library of Medicine, DailyMed
Need Barhemsys 5 mg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.